A case of nivolumab-induced cutaneous sarcoidosis in a patient with renal cell carcinoma

Introduction: Binding of programmed cell death 1 (PD-1) ligands to PD-1 receptors found on T cells, inhibits T-cell proliferation and contributes to immune tolerance and inhibition of tumor surveillance. Nivolumab is a monoclonal antibody that binds to PD-1 receptor and inhibits this pathway. Given its antitumor capabilities, this medication was recently approved in Canada and the U.S. for the treatment of unresectable or metastatic melanoma, metastatic nonsmall cell lung cancer, renal carcinoma, and classical Hodgkin lymphoma.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research